



## ArQule to Present at the 30th Annual Roth Conference on March 12, 2018

March 5, 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--Mar. 5, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will present at the 30<sup>th</sup> Annual Roth Conference on March 12<sup>th</sup>, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California.

You can access the live webcast of the presentation via the "Investors & Media" section of our website, [www.arqule.com](http://www.arqule.com), under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation.

### About ArQule

[ArQule](http://www.arqule.com) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making [ArQule](http://www.arqule.com) a leader among companies our size in precision medicine. ArQule's proprietary pipeline includes: Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA and in phase 1b for multiple oncology indications; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), as well as in multiple oncology indications; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a  $\gamma$ -lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options. ArQule's current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company's proprietary library of compounds. You can follow us on [Twitter](https://twitter.com/ArQule) and [LinkedIn](https://www.linkedin.com/company/arqule).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180305005056/en/>

Source: ArQule, Inc.

ArQule, Inc.

Dawn Schottland, 781-994-0300

Vice President, Investor Relations/Corp. Communications

[www.arqule.com](http://www.arqule.com)